Mark W. Skinner

1.8k total citations
59 papers, 1.1k citations indexed

About

Mark W. Skinner is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Mark W. Skinner has authored 59 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 9 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Mark W. Skinner's work include Hemophilia Treatment and Research (51 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Platelet Disorders and Treatments (6 papers). Mark W. Skinner is often cited by papers focused on Hemophilia Treatment and Research (51 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Platelet Disorders and Treatments (6 papers). Mark W. Skinner collaborates with scholars based in Canada, United States and United Kingdom. Mark W. Skinner's co-authors include Brian O’Mahony, Alfonso Iorio, Glenn F. Pierce, Barbara A. Konkle, Diane J. Nugent, Jamie O’Hara, Declan Noone, Randall Curtis, Jeffrey S. Stonebraker and David Page and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Molecular Therapy.

In The Last Decade

Mark W. Skinner

58 papers receiving 1.0k citations

Peers

Countries citing papers authored by Mark W. Skinner

Since Specialization

Citations

This map shows the geographic impact of Mark W. Skinner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Skinner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Skinner more than expected).

Fields of papers citing papers by Mark W. Skinner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Skinner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Skinner. The network helps show where Mark W. Skinner may publish in the future.

Co-authorship network of co-authors of Mark W. Skinner

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Skinner. A scholar is included among the top collaborators of Mark W. Skinner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Skinner. Mark W. Skinner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiative 2024 ·Haemophilia ·Elizabeth Clearfield, Benjamin Kim, (unknown), Nathan T. Connell, (unknown), Michelle Lavin, (unknown), Elía M. Ayoub, Veronica H. Flood, (unknown), Mark W. Skinner, Paula James, (unknown)	3
2	Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study 2024 ·Haemophilia ·Randall Curtis, Joanne Wu, Alfonso Iorio, (unknown), Michael B. Nichol, Declan Noone, Brian O’Mahony, David Page, Jeffrey S. Stonebraker, (unknown), Elizabeth Clearfield, Mark W. Skinner, Federico Germini	1
3	Development of the World Federation of Hemophilia Shared Decision‐Making Tool 2024 ·Haemophilia ·Donna Coffin, Mark W. Skinner, Courtney D. Thornburg, (unknown), (unknown), (unknown), (unknown), (unknown), Glenn F. Pierce	4
4	Hemophilia gene therapy: first, do no harm 2023 ·Journal of Thrombosis and Haemostasis ·(unknown), Radosław Kaczmarek, Glenn F. Pierce, Declan Noone, Brian O’Mahony, David Page, (unknown), Mark W. Skinner	11
5	Data sharing to advance gene‐targeted therapies in rare diseases 2023 ·American Journal of Medical Genetics Part C Seminars in Medical Genetics ·(unknown), Erika F. Augustine, Amy Brower, Thomas Defay, Richard S. Finkel, Amy L. McGuire, Mark W. Skinner, Timothy W. Yu	7
6	Gene‐targeted therapies: Towards equitable development, diagnosis, and access 2023 ·American Journal of Medical Genetics Part C Seminars in Medical Genetics ·Amy Gaviglio, Mark W. Skinner, (unknown), Richard S. Finkel, Erika F. Augustine, Aaron J. Goldenberg	10
7	Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science 2023 ·Expert Review of Hematology ·Vanessa R. Byams, Judith Baker, (unknown), Nathan T. Connell, Melissa Creary, Randall Curtis, Alexis Dinno, Christine Guelcher, Michelle Kim, Roshni Kulkarni, Susan Lattimore, (unknown), (unknown), Mark W. Skinner, (unknown), (unknown), (unknown), (unknown), (unknown), Tyler W. Buckner	8
8	Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years 2022 ·The Lancet Haematology ·Glenn F. Pierce, (unknown), Saliou Diop, Amy L. Dunn, Magdy El Ekiaby, Radosław Kaczmarek, Barbara A. Konkle, Steven W. Pipe, Mark W. Skinner, Leonard A. Valentino, (unknown), (unknown), (unknown), (unknown)	38
9	Identified unmet needs and proposed solutions in mild‐to‐moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts 2021 ·Haemophilia ·Christopher Walsh, Lisa Boggio, (unknown), Rachel J. Miller, (unknown), (unknown), (unknown), (unknown), Kim Baumann, (unknown), Mark W. Skinner, (unknown), (unknown), (unknown), (unknown), Michelle Witkop, (unknown), David L. Cooper	9
10	User-Centered Development and Testing of the Online Patient-Reported Outcomes, Burdens, and Experiences (PROBE) Survey and the myPROBE App and Integration With the Canadian Bleeding Disorder Registry: Mixed Methods Study 2021 ·JMIR Human Factors ·Federico Germini, Victoria Borg Debono, David Page, (unknown), (unknown), Chris Cotoi, (unknown), (unknown), Mark W. Skinner, Alfonso Iorio, (unknown)	4
11	The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies 2021 ·Haemophilia ·Mark W. Skinner, Claude Négrier, Ido Paz‐Priel, Sammy Chebon, Víctor Jiménez‐Yuste, Michael U. Callaghan, Michaela Lehle, Markus Niggli, Johnny Mahlangu, Amy D. Shapiro, Midori Shima, Avrita Campinha‐Bacote, Gallia G. Levy, Johannes Oldenburg, Sylvia von Mackensen, Steven W. Pipe	34
12	Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders 2021 ·Haemophilia ·Radosław Kaczmarek, Magdy El Ekiaby, Daniel P. Hart, Cédric Hermans, Michael Makris, Declan Noone, Brian O’Mahony, David Page, Flora Peyvandi, Steven W. Pipe, (unknown), (unknown), Mark W. Skinner, Alok Srivastava, (unknown), Glenn F. Pierce	6
13	The potential impact of gene therapy on health-related quality of life (HRQoL) domains in haemophilia 2021 ·SHILAP Revista de lepidopterología ·Monika Bullinger, (unknown), Hannah B Lewis, Wolfgang Miesbach, Sandra Nolte, Jamie O’Hara, Brian O’Mahony, Debra Pollard, Mark W. Skinner, Jennifer Quinn	4
14	Evidence of a disability paradox in patient‐reported outcomes in haemophilia 2021 ·Haemophilia ·Jamie O’Hara, Antony P. Martin, Diane J. Nugent, Michelle Witkop, Tyler W. Buckner, Mark W. Skinner, Brian O’Mahony, Brendan Mulhern, (unknown), Nanxin Li, Eileen K. Sawyer	33
15	The World Federation of Hemophilia Annual Global Survey 1999‐2018 2020 ·Haemophilia ·Jeffrey S. Stonebraker, Paula Bolton‐Maggs, Mark Brooker, Bruce L. Evatt, Alfonso Iorio, Michael Makris, Brian O’Mahony, Mark W. Skinner, Donna Coffin, Glenn F. Pierce, (unknown)	74
16	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor? 2020 ·Haemophilia ·Glenn F. Pierce, Radosław Kaczmarek, Declan Noone, Brian O’Mahony, David Page, Mark W. Skinner	19
17	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH 2020 ·Journal of Thrombosis and Haemostasis ·Barbara A. Konkle, (unknown), Donna Coffin, (unknown), (unknown), Lindsey A. George, Alfonso Iorio, Brian O’Mahony, Steven W. Pipe, Mark W. Skinner, (unknown), Flora Peyvandi, Johnny Mahlangu	35
18	Non‐severe haemophilia: Is it benign? – Insights from the PROBE study 2020 ·Haemophilia ·Chatree Chai‐Adisaksopha, Declan Noone, Randall Curtis, (unknown), Michael B. Nichol, Federico Germini, Brian O’Mahony, David Page, Jeffrey S. Stonebraker, Mark W. Skinner, Alfonso Iorio	25
19	Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project 2018 ·Haemophilia ·Alfonso Iorio, Mark W. Skinner, Elizabeth Clearfield, Donna A. Messner, Glenn F. Pierce, Michelle Witkop, Sean Tunis, (unknown)	76
20	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire 2018 ·BMJ Open ·Chatree Chai‐Adisaksopha, Mark W. Skinner, Randall Curtis, (unknown), Michael B. Nichol, Declan Noone, Brian O’Mahony, David Page, Jeffrey S. Stonebraker, Lehana Thabane, Mark Crowther, Alfonso Iorio	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact